+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Decreased levels of procoagulant phospholipids in bleeding patients treated by vitamin K antagonists



Decreased levels of procoagulant phospholipids in bleeding patients treated by vitamin K antagonists



Thrombosis Research 137: 36-40



International Normalized Ratio (INR) is currently used to monitor vitamin K antagonist therapy, and the bleeding incidence becomes exponential for INR>4.5. Inversely, more than 50% of patients with a supratherapeutic INR are asymptomatic. Therefore it could be of interest to identify patients with a higher bleeding risk. Microparticles derived from different cell types express procoagulant phospholipids (PPL) which can be evaluated by a chronometric coagulation assay where a shortening of the clotting times is associated with increased levels of PPL. In a series of 174 consecutive patients referred to our Emergency Department with an INR>5, median level of PPL was significantly (p=0.004) lower (38.2s) in the 119 asymptomatic patients than in patients with nonmajor (43.6s, n=35) or major bleeding (46.6s, n=19), indicating higher levels of procoagulant phospholipids in asymptomatic patients. By receiver operating characteristic curve analysis, a cut-off of 43.5s discriminated patients with higher haemorrhagic risk (area under the curve=0.648). In contrast, thrombomodulin levels, quantified either by immunological or functional assays were not significantly different between both groups. In conclusion, evaluation of PPL could be of interest to define the haemorrhagic risk of VKA- treated patients.

(PDF emailed within 0-6 h: $19.90)

Accession: 057564920

Download citation: RISBibTeXText

PMID: 26632514

DOI: 10.1016/j.thromres.2015.11.028


Related references

Decreased procoagulant phospholipids in patients treated by vitamin K antagonists. Thrombosis Research 130(3): 491-494, 2013

Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thrombosis Research 136(4): 749-753, 2016

Risk factors associated with a thrombotic or bleeding event in patients treated with vitamin K antagonists. Journal des Maladies Vasculaires 39(4): 248-255, 2016

Platelet dysfunction in thrombosis patients treated with vitamin K antagonists and recurrent bleeding. Plos One 8(5): E64112-E64112, 2014

Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. Thrombosis and Haemostasis 115(2): 424-432, 2015

Decreased generation of procoagulant platelets detected by flow cytometric analysis in patients with bleeding diathesis. Cytometry. Part B, Clinical Cytometry 86(6): 397-409, 2015

Risk Factors for Bleeding in Hospitalized at Risk Patients With an INR of 5 or More Treated With Vitamin K Antagonists. Medicine 94(52): E2366-E2366, 2016

Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 374(9706): 1967-1974, 2010

Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics). Thrombosis and Haemostasis 107(6): 1100-1106, 2012

Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Circulation 132(13): 1252-1260, 2016

Guideline-concordant administration of prothrombin complex concentrate and vitamin K is associated with decreased mortality in patients with severe bleeding under vitamin K antagonist treatment (EPAHK study). Critical Care 18(2): R81-R81, 2015

Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolism. Vascular Pharmacology 87: 242-247, 2016

French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thrombosis Research 126(3): E167-E174, 2010

Levels of vitamin K-dependent procoagulant and anticoagulant proteins in over-anticoagulated patients. Blood Coagulation & Fibrinolysis 13(8): 733-739, 2002

Decreased activity of soluble thrombomodulin and plasma procoagulant phospholipids in childhood bone marrow transplantation with severe complications. Thrombosis Research 128(3): 261-267, 2012